AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9744983 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene hydrochloride for osteoporosis prevention
Number of subjects: 619
Study 8141110 — intervention group
Group type: EXPERIMENTAL
Intervention: DHAD
Number of subjects: 80
Study 8141110 — intervention group
Group type: EXPERIMENTAL
Intervention: VP-16
Number of subjects: 80
Study 8141110 — intervention group
Group type: EXPERIMENTAL
Intervention: aclacinomycin
Number of subjects: 80
Study 8141110 — intervention group
Group type: EXPERIMENTAL
Intervention: spirogermanium
Number of subjects: 80
Study 8141110 — intervention group
Group type: COMPARATOR
Intervention: Control (all treatments)
Number of subjects: 80
Study 3153712 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolipram
Number of subjects: 0
Study 3153712 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 0
Study 30144989 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic agitation
Number of subjects: 168
Study 30144989 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive ultrasonic irrigation
Number of subjects: 168
Study 30144989 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual dynamic agitation (MDA)
Number of subjects: 168
Study 30144989 — intervention group
Group type: COMPARATOR
Intervention: Needle irrigation
Number of subjects: 168
Study 27289035 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical clown participation
Number of subjects: 80
Study 27289035 — intervention group
Group type: COMPARATOR
Intervention: No medical clown participation
Number of subjects: 80
Study 23847109 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol phenylbutyrate (GPB) at 6 mL orally twice-daily
Number of subjects: 178
Study 23847109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study 22259063 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin (50 μg)
Number of subjects: 6
Study 22259063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 20216424 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate initiation of paliperidone extended release (ER)
Number of subjects: 201
Study 20216424 — intervention group
Group type: COMPARATOR
Intervention: Delayed initiation of paliperidone extended release (ER)
Number of subjects: 201
Study 18567539 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg oral doxycycline once per day for 14 days
Number of subjects: 118
Study 18567539 — intervention group
Group type: COMPARATOR
Intervention: 2 g intravenous ceftriaxone once per day for 14 days
Number of subjects: 118
Study 18567539 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects possibly related to treatment in doxycycline group
Number of subjects: 118
Study 18567539 — intervention group
Group type: COMPARATOR
Intervention: Side effects possibly related to treatment in ceftriaxone group
Number of subjects: 118
Study 15838068 — intervention group
Group type: EXPERIMENTAL
Intervention: Wegener granulomatosis patients
Number of subjects: 180
Study 12053584 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CD80 monoclonal antibodies
Number of subjects: 0
Study 12053584 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CD86 monoclonal antibodies
Number of subjects: 0
Study 10851856 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet enriched with phytoestrogens
Number of subjects: 82
Study 10851856 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for acceptance
Number of subjects: 82
Study 10851856 — intervention group
Group type: COMPARATOR
Intervention: Reasons for refusal
Number of subjects: 82
Study 8697157 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 g of ethanol per kilogram of body weight diluted to 15% in juice
Number of subjects: 20
Study 8697157 — intervention group
Group type: COMPARATOR
Intervention: Juice (control)
Number of subjects: 20
Study 1986498 — intervention group
Group type: COMPARATOR
Intervention: Coronary angioplasty
Number of subjects: 641
Study 1986498 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass graft surgery
Number of subjects: 641
Study 1986498 — intervention group
Group type: COMPARATOR
Intervention: Hospital mortality
Number of subjects: 641
Study 1986498 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior coronary artery bypass graft surgery
Number of subjects: 641
Study 1986498 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior hypertension
Number of subjects: 641
Study 1986498 — intervention group
Group type: COMPARATOR
Intervention: Evidence of acute myocardial infarction (AMI)
Number of subjects: 641
Study 6604940 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Number of subjects: 41
Study 6604940 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen capsules
Number of subjects: 41
Study 6604940 — intervention group
Group type: EXPERIMENTAL
Intervention: Biovail capsules
Number of subjects: 41
Study 6604940 — intervention group
Group type: EXPERIMENTAL
Intervention: IBP tablets
Number of subjects: 41
Study 30695089 — intervention group
Group type: EXPERIMENTAL
Intervention: Conical interface (CI) implants
Number of subjects: 111
Study 30695089 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat-to-flat interface (FI) implants
Number of subjects: 111
Study 30695089 — intervention group
Group type: EXPERIMENTAL
Intervention: Platform-switched interface (PS) implants
Number of subjects: 111
Study 28169430 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine 80 mg/m², days 1, 2; Bortezomib 1.3 mg/m², days 1, 8, 15; Dexamethasone 20 mg, days 1, 2, 8, 9, 15, 16 every 28 days (up to 8 cycles), then maintenance 1.3 mg/m² IV bortezomib every 2 weeks
Number of subjects: 59
Study 28169430 — intervention group
Group type: COMPARATOR
Intervention: Original regimen: Bendamustine 80 mg/m², days 1, 4; Bortezomib 1.3 mg/m², days 1, 4, 8, 11; Dexamethasone 40 mg, days 1, 2, 3, 4 on a 28-day cycle (up to 8 cycles)
Number of subjects: 59
Study 25656287 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (19 fractions of 34 Gy in 65 weeks, three fractions per week)
Number of subjects: 820
Study 25656287 — intervention group
Group type: COMPARATOR
Intervention: Standard fractionated radiotherapy (39 fractions of 2 Gy in 8 weeks, five fractions per week)
Number of subjects: 820
Study 25656287 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Number of subjects: 820
Study 25656287 — intervention group
Group type: COMPARATOR
Intervention: Standard fractionated radiotherapy
Number of subjects: 820
Study 24477097 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal SBP increase (10 mmHg)
Number of subjects: 768
Study 24477097 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal DBP increase (10 mmHg)
Number of subjects: 768
Study 24477097 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal DBP
Number of subjects: 768
Study 23084676 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar coagulation (BC group)
Number of subjects: 100
Study 23084676 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic suturing (LS group)
Number of subjects: 100
Study 23084676 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (BC and LS)
Number of subjects: 100
Study 19783569 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain-free walking
Number of subjects: 28
Study 19783569 — intervention group
Group type: EXPERIMENTAL
Intervention: Painful walking
Number of subjects: 28
Study 18176356 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated consultation with a gastroenterologist prior to colonoscopy (group E)
Number of subjects: 31
Study 18176356 — intervention group
Group type: COMPARATOR
Intervention: Usual information delivery (group NE)
Number of subjects: 31
Study 15766465 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone (500 microg/12 h), salmeterol (50 microg/12 h), and placebo
Number of subjects: 22
Study 15766465 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone, tiotropium (18 microg/24 h), and placebo
Number of subjects: 22
Study 15766465 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone, salmeterol, and tiotropium
Number of subjects: 22
Study 15766465 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol
Number of subjects: 22
Study 15766465 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium
Number of subjects: 22
Study 12076217 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 80 mg/d
Number of subjects: 1677
Study 12076217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1677
Study 12076217 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (subgroup analysis)
Number of subjects: 1677
Study 9789513 — intervention group
Group type: EXPERIMENTAL
Intervention: S + W (salmeterol/weaning)
Number of subjects: 386
Study 9789513 — intervention group
Group type: COMPARATOR
Intervention: P + W (placebo/weaning)
Number of subjects: 386
Study 9789513 — intervention group
Group type: COMPARATOR
Intervention: P + NW (placebo/no weaning)
Number of subjects: 386
Study 8647059 — intervention group
Group type: EXPERIMENTAL
Intervention: Early neonatal exposure to cow's milk formula feeding
Number of subjects: 0
Study 8647059 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk
Number of subjects: 0
Study 8647059 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased IgE response to cow's milk protein
Number of subjects: 0
Study 8647059 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery from CMPA/CMPI
Number of subjects: 0
Study 8647059 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse reactions to other foods (egg, soy, peanut, citrus)
Number of subjects: 0
Study 8647059 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergy to environmental inhalant allergens
Number of subjects: 0
Study 8647059 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic tests for CMPA
Number of subjects: 0
Study 8647059 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind placebo-controlled challenges (DBPCFC)
Number of subjects: 0
Study 8647059 — intervention group
Group type: EXPERIMENTAL
Intervention: Open controlled challenges
Number of subjects: 0
Study 3533889 — intervention group
Group type: EXPERIMENTAL
Intervention: slow release trimethoprim
Number of subjects: 151
Study 3533889 — intervention group
Group type: COMPARATOR
Intervention: co‐trimoxazole
Number of subjects: 151
Study 29246580 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal Tension Glaucoma (NTG)
Number of subjects: 127
Study 29246580 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Open-Angle Glaucoma (POAG)
Number of subjects: 127
Study 29246580 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls
Number of subjects: 127
Study 27075710 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (10 mg once daily for 7 days)
Number of subjects: 241
Study 27075710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 241
Study 27075710 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 241
Study 25192562 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% concentration cream composed of marjoram, black pepper, lavender, and peppermint
Number of subjects: 60
Study 25192562 — intervention group
Group type: COMPARATOR
Intervention: Unscented cream
Number of subjects: 60
Study 23268664 — intervention group
Group type: EXPERIMENTAL
Intervention: Early CPAP
Number of subjects: 1316
Study 23268664 — intervention group
Group type: COMPARATOR
Intervention: Early surfactant administration
Number of subjects: 1316
Study 23268664 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower oxygen saturation target (85 to 89%)
Number of subjects: 1316
Study 23268664 — intervention group
Group type: COMPARATOR
Intervention: Higher oxygen saturation target (91 to 95%)
Number of subjects: 1316
Study 21040558 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil-based analgo-sedation (RS)
Number of subjects: 0
Study 21040558 — intervention group
Group type: COMPARATOR
Intervention: Conventional analgesia and sedation (CS)
Number of subjects: 0
Study 18510645 — intervention group
Group type: EXPERIMENTAL
Intervention: CNI withdrawal after alemtuzumab induction
Number of subjects: 40
Study 18510645 — intervention group
Group type: COMPARATOR
Intervention: CNI continuation
Number of subjects: 40
Study 19817641 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural honey for 8 weeks
Number of subjects: 48
Study 19817641 — intervention group
Group type: COMPARATOR
Intervention: Control group (no honey)
Number of subjects: 48
Study 14593452 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip protectors
Number of subjects: 0
Study 14593452 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard definitions of adherence
Number of subjects: 0
Study 11380379 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersion in warm water during labor
Number of subjects: 274
Study 11380379 — intervention group
Group type: COMPARATOR
Intervention: Routine care (nonbath group)
Number of subjects: 274
Study 9296938 — intervention group
Group type: COMPARATOR
Intervention: Maternal serum activities on the third and fifth day of puerperium in women with mild and moderate EPH-Gestosis
Number of subjects: 0
Study 9296938 — intervention group
Group type: COMPARATOR
Intervention: Maternal serum activities on the first day of puerperium in patients with moderate EPH-Gestosis
Number of subjects: 0
Study 9296938 — intervention group
Group type: COMPARATOR
Intervention: Umbilical blood activities in patients with moderate EPH-Gestosis
Number of subjects: 0
Study 9296938 — intervention group
Group type: COMPARATOR
Intervention: Amniotic fluid enzyme activity in cases of mild and moderate EPH-Gestosis
Number of subjects: 0
Study 9296938 — intervention group
Group type: COMPARATOR
Intervention: Extraplacental blood enzyme activity in cases of mild and moderate EPH-Gestosis
Number of subjects: 0
Study 9296938 — intervention group
Group type: COMPARATOR
Intervention: Umbilical cord blood sera enzyme activity
Number of subjects: 0
Study 8390278 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalaprilat (ACE inhibitor)
Number of subjects: 0
Study 8390278 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasoactive intestinal polypeptide (VIP) infusion
Number of subjects: 0
Study 3550373 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms of Cr as chromic chloride for three months
Number of subjects: 8
Study 4946956 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacteriophage preparation (10^8 to 10^9 pfu/ml), given by mouth (25 ml for adults, 20 ml for children) for 3 days, with some receiving an intramuscular injection (20 ml) on the first day.
Number of subjects: 0
Study 4946956 — intervention group
Group type: COMPARATOR
Intervention: Standard tetracycline regimen
Number of subjects: 0
Study 4946956 — intervention group
Group type: COMPARATOR
Intervention: Placebo preparation
Number of subjects: 0
Study 30901609 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐1 and cisplatin (SP)
Number of subjects: 179
Study 30901609 — intervention group
Group type: EXPERIMENTAL
Intervention: oxaliplatin and 5‐FU (FOLFOX)
Number of subjects: 179
Study 30901609 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel and 5‐FU (DF)
Number of subjects: 179
Study 30901609 — intervention group
Group type: EXPERIMENTAL
Intervention: paclitaxel and 5‐FU (PF)
Number of subjects: 179
Study 30901609 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum group
Number of subjects: 179
Study 30901609 — intervention group
Group type: EXPERIMENTAL
Intervention: Starting with platinum
Number of subjects: 179
Study 30901609 — intervention group
Group type: EXPERIMENTAL
Intervention: Starting with taxane
Number of subjects: 179
Study 29916874 — intervention group
Group type: EXPERIMENTAL
Intervention: Early laparoscopic cholecystectomy (ELC)
Number of subjects: 86
Study 26079438 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-system therapy (SST)
Number of subjects: 101
Study 26079438 — intervention group
Group type: COMPARATOR
Intervention: Pain education
Number of subjects: 101
Study 26079438 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 101
Study 24787916 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Training (CT) for seven weeks
Number of subjects: 40
Study 24787916 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (waitlist control) for seven weeks
Number of subjects: 40
Study 21789761 — intervention group
Group type: EXPERIMENTAL
Intervention: VAVD at -40 mmHg
Number of subjects: 162
Study 21789761 — intervention group
Group type: EXPERIMENTAL
Intervention: VAVD at -80 mmHg
Number of subjects: 162
Study 21789761 — intervention group
Group type: COMPARATOR
Intervention: Gravity siphon
Number of subjects: 162
Study 20851726 — intervention group
Group type: EXPERIMENTAL
Intervention: Food liking ratings for chocolate bar, muffin, banana, cola, cornflakes, potato chips, hot chocolate drink, and ice-cream
Number of subjects: 27
Study 20851726 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiarity ratings for chocolate bar, muffin, banana, cola, cornflakes, potato chips, hot chocolate drink, and ice-cream
Number of subjects: 27
Study 20851726 — intervention group
Group type: EXPERIMENTAL
Intervention: Expected satiation (ES) ratings for chocolate bar, muffin, banana, cola, cornflakes, potato chips, hot chocolate drink, and ice-cream
Number of subjects: 27
Study 17978107 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6% chlorhexidine vaginal and neonatal wipes
Number of subjects: 203
Study 17978107 — intervention group
Group type: COMPARATOR
Intervention: Saline vaginal and neonatal wipes
Number of subjects: 203
Study 15608836 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (50 mg orally twice a day for 6 months)
Number of subjects: 258
Study 15608836 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral placebo twice a day for 6 months)
Number of subjects: 258
Study 11665370 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcified alloplast as a gap-filling material
Number of subjects: 14
Study 11665370 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental computed tomography scans and periodontal measurements
Number of subjects: 14
Study 11665370 — intervention group
Group type: COMPARATOR
Intervention: Demineralized freeze-dried bone (control)
Number of subjects: 14
Study 9639501 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF + epo (arm A: G‐CSF for 4 weeks followed by combination for 12 weeks; arm B: epo for 8 weeks followed by combination for 10 weeks)
Number of subjects: 71
Study 9639501 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term maintenance treatment
Number of subjects: 71
Study 9639501 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 71
Study 7978186 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexital-alfentanil (M-A)
Number of subjects: 27
Study 7978186 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-alfentanil (P-A)
Number of subjects: 27
Study 7978186 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane-nitrous oxide (Iso)
Number of subjects: 27
Study 2471260 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprinosine (IP)
Number of subjects: 38
Study 2471260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 29795366 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention group (n=209)
Number of subjects: 415
Study 29795366 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=206)
Number of subjects: 415
Study 28213750 — intervention group
Group type: EXPERIMENTAL
Intervention: High EPA fish oil (750 mg EPA, 50 mg DHA)
Number of subjects: 27
Study 28213750 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 27
Study 28213750 — intervention group
Group type: EXPERIMENTAL
Intervention: Low EPA fish oil (150 mg EPA, 100 mg DHA)
Number of subjects: 27
Study 26303208 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate dialysate (CD)
Number of subjects: 0
Study 26303208 — intervention group
Group type: COMPARATOR
Intervention: Acetate dialysate (AD)
Number of subjects: 0
Study 23639301 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 177
Study 21547610 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported healthcare provider discrimination
Number of subjects: 10409
Study 21547610 — intervention group
Group type: COMPARATOR
Intervention: Medication intensification for hyperglycemia
Number of subjects: 10409
Study 21547610 — intervention group
Group type: COMPARATOR
Intervention: Medication intensification for hyperlipidemia
Number of subjects: 10409
Study 21547610 — intervention group
Group type: COMPARATOR
Intervention: Medication intensification for hypertension
Number of subjects: 10409
Study 21547610 — intervention group
Group type: COMPARATOR
Intervention: Medication intensification for any risk factor
Number of subjects: 10409
Study 18469260 — intervention group
Group type: COMPARATOR
Intervention: Control formula
Number of subjects: 284
Study 18469260 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulas containing Bifidobacterium longum BL999 + Lactobacillus rhamnosus LPR
Number of subjects: 284
Study 18469260 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulas containing Bifidobacterium longum BL999 + Lactobacillus rhamnosus LPR + 4 g/L GOS/SCFOS
Number of subjects: 284
Study 18469260 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulas containing Bifidobacterium longum BL999 + Lactobacillus paracasei ST11 + 4 g/L GOS/SCFOS
Number of subjects: 284
Study 17319473 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (20 mg) and Niacin(ER) (500 mg) combination once daily, with dose escalation to Niacin(ER) (1000 mg) in 11 patients based on lipid parameters at 8 weeks.
Number of subjects: 131
Study 12526245 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue (Quixil)
Number of subjects: 204
Study 12526245 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue (Quixil) + transseptal suturing
Number of subjects: 204
Study 12526245 — intervention group
Group type: COMPARATOR
Intervention: Nasal packing
Number of subjects: 204
Study 10599912 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrier membranes (Guidor or Resolut or Periodontal (e‐PTFE) material)
Number of subjects: 40
Study 10599912 — intervention group
Group type: EXPERIMENTAL
Intervention: Emdogain (enamel matrix proteins)
Number of subjects: 40
Study 10599912 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (no barrier placement, vehicle PGA gel used as placebo)
Number of subjects: 40
Study 7556256 — intervention group
Group type: EXPERIMENTAL
Intervention: iobitridol (30% iodine)
Number of subjects: 40
Study 7556256 — intervention group
Group type: COMPARATOR
Intervention: iohexol
Number of subjects: 40